Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, causing pain, stiffness, and progressive fusion of the vertebrae. It typically begins in early adulthood and can lead to a hunched-forward posture if untreated. AS is part of the broader category of axial spondyloarthritis.
You may qualify for clinical trials that provide Humira at no cost
Clinical trials may give you access to this treatment while helping advance medical research
Search TrialsStandard step therapy requires failure of at least 2 NSAIDs (each for ≥2–4 weeks at maximum tolerated dose) before biologic therapy. Conventional DMARDs (methotrexate, sulfasalazine) are only appropriate for peripheral joint involvement — not axial disease. TNF inhibitors are the established first-line biologics, with IL-17 inhibitors (Cosentyx, Taltz) as alternatives.
Must fail at least 2 NSAIDs before biologic therapy
Very Common
HLA-B27 testing or imaging not submitted
Common
Conventional DMARD trial required (inappropriate for axial disease)
Common
Biosimilar preferred over brand biologic
Occasional
IL-17 inhibitor denied without TNF inhibitor failure
Occasional
- 1.Document failure of ≥2 NSAIDs with specific drugs, doses, duration, and reasons for failure
- 2.Include imaging: sacroiliac joint X-ray or MRI showing sacroiliitis
- 3.Document BASDAI or ASDAS disease activity scores
- 4.Emphasize that conventional DMARDs are NOT effective for axial disease — if insurer requires them, challenge with guidelines
- 5.Cite ACR/SAA/SPARTAN 2019 guidelines supporting biologic therapy after NSAID failure
Active clinical trials that may provide treatment at no cost.
Copay cards, patient assistance programs, and foundation grants for this condition's treatments.
Want to know what you'll actually pay?
Estimate your annual out-of-pocket cost with and without assistance programs.
Estimate My CostsDenied for Ankylosing Spondylitis Treatment?
Ellen can decode your denial, find your appeal strategy, and generate your appeal letter — free.